| ²é¿´: 398 | »Ø¸´: 2 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
wqssfj1Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
|
[ÇóÖú]
ÇóÖú·Òë
|
|
|
The MAH must ensure that the system of pharmacovigilance, presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market. in place ÔÚ¾äÖеÄÒâ˼ÊÇʲô£¿ лл£¡ |
» ²ÂÄãϲ»¶
312Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
0703µ÷¼Á£¬Ò»Ö¾Ô¸Ìì½ò´óѧ319·Ö
ÒѾÓÐ9È˻ظ´
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ10È˻ظ´
ר˶0854³õÊÔ¿¼²Ä¿Æ»ù£¬Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
085600£¬320·ÖÇóµ÷¼Á
ÒѾÓÐ17È˻ظ´
297·Ö083200ÇóÖú
ÒѾÓÐ3È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸±±½»´ó²ÄÁϹ¤³Ì×Ü·Ö358Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ ²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á
ÒѾÓÐ7È˻ظ´
weichin
Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)
- ·ÒëEPI: 183
- Ó¦Öú: 18 (СѧÉú)
- ½ð±Ò: 9734.7
- ºì»¨: 17
- Ìû×Ó: 4116
- ÔÚÏß: 345.2Сʱ
- ³æºÅ: 1490943
- ×¢²á: 2011-11-14
- רҵ: ½á¹¹ÌÕ´É

2Â¥2012-03-23 15:32:17
natisean
½ð³æ (СÓÐÃûÆø)
- ·ÒëEPI: 4
- Ó¦Öú: 6 (Ó×¶ùÔ°)
- ½ð±Ò: 1047.1
- ºì»¨: 23
- Ìû×Ó: 104
- ÔÚÏß: 18.9Сʱ
- ³æºÅ: 1261244
- ×¢²á: 2011-04-10
- רҵ: ¾ÛºÏÎï¹²»ìÓ븴ºÏ²ÄÁÏ
3Â¥2012-03-23 16:19:59














»Ø¸´´ËÂ¥